Ascendis Pharma A/S Statistics
Share Statistics
Ascendis Pharma A/S has 60.37M
shares outstanding. The number of shares has increased by 5.7%
in one year.
Shares Outstanding | 60.37M |
Shares Change (YoY) | 5.7% |
Shares Change (QoQ) | 0.14% |
Owned by Institutions (%) | 99.99% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 41 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.76M, so 6.21% of the outstanding
shares have been sold short.
Short Interest | 3.76M |
Short % of Shares Out | 6.21% |
Short % of Float | 7.47% |
Short Ratio (days to cover) | 6.13 |
Valuation Ratios
The PE ratio is -20.36 and the forward
PE ratio is 90.39.
Ascendis Pharma A/S's PEG ratio is
0.86.
PE Ratio | -20.36 |
Forward PE | 90.39 |
PS Ratio | 21.17 |
Forward PS | 3.1 |
PB Ratio | -72.81 |
P/FCF Ratio | -25.02 |
PEG Ratio | 0.86 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ascendis Pharma A/S.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17,
with a Debt / Equity ratio of -8.1.
Current Ratio | 1.17 |
Quick Ratio | 0.84 |
Debt / Equity | -8.1 |
Debt / EBITDA | -2.95 |
Debt / FCF | -2.78 |
Interest Coverage | -4.26 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $357,562.44 |
Profits Per Employee | $-371,764.01 |
Employee Count | 1,017 |
Asset Turnover | 0.31 |
Inventory Turnover | 0.15 |
Taxes
Income Tax | 4.84M |
Effective Tax Rate | -1.3% |
Stock Price Statistics
The stock price has increased by 20.44% in the
last 52 weeks. The beta is 0.4, so Ascendis Pharma A/S's
price volatility has been higher than the market average.
Beta | 0.4 |
52-Week Price Change | 20.44% |
50-Day Moving Average | 158.13 |
200-Day Moving Average | 141.19 |
Relative Strength Index (RSI) | 53.99 |
Average Volume (20 Days) | 503,567 |
Income Statement
In the last 12 months, Ascendis Pharma A/S had revenue of 363.64M
and earned -378.08M
in profits. Earnings per share was -6.53.
Revenue | 363.64M |
Gross Profit | 319.38M |
Operating Income | -278.76M |
Net Income | -378.08M |
EBITDA | -290.02M |
EBIT | -307.74M |
Earnings Per Share (EPS) | -6.53 |
Full Income Statement Balance Sheet
The company has 559.54M in cash and 856.62M in
debt, giving a net cash position of -297.07M.
Cash & Cash Equivalents | 559.54M |
Total Debt | 856.62M |
Net Cash | -297.07M |
Retained Earnings | n/a |
Total Assets | 1.06B |
Working Capital | 35.98M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -306.2M
and capital expenditures -1.43M, giving a free cash flow of -307.62M.
Operating Cash Flow | -306.2M |
Capital Expenditures | -1.43M |
Free Cash Flow | -307.62M |
FCF Per Share | -5.31 |
Full Cash Flow Statement Margins
Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.
Gross Margin | 87.83% |
Operating Margin | -76.66% |
Pretax Margin | -102.64% |
Profit Margin | -103.97% |
EBITDA Margin | -79.76% |
EBIT Margin | -76.66% |
FCF Margin | -84.6% |